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Dear Editor,
Our immune system constantly interacts with our internal environ-
ment, protects us from our external environment and provides the
inherent knowledge to sense the difference between friend and foe.
Therefore, the immune system is one of the most dynamic body
components in determining our state of health or disease. The
importance of immune-based disorders is highlighted by the fact that
immune-mediated inflammatory diseases are known to affect nearly
20% of the U.S. population. These conditions, which include juve-
nile-onset diabetes, rheumatoid arthritis, multiple sclerosis, asthma,
systemic lupus erythematosus and acquired immune deficiency syn-
drome, lead to chronic debilitation, life-long illness, protracted mor-
bidity and result in great medical costs. The immune system also has
a major involvement in post-transplant rejection and in the body’s
ability to fight invading cancer cells. 
Despite of these seemingly unconnected diseases, basic immu-
nologists are in a prominent position to apprehend a broader picture
under a cohesive paradigm. This forefront of future therapeutic
strategies relies on the successful applications of genetic, molecu-
lar and cellular immunology to prevent, treat and cure the problems
caused by immune-based disorders. The translational aspects of
research that are directly related to patient care require integrated,
multidisciplinary strategies involving teams skilled in basic biology
and clinical investigation, ethics and regulatory issues. To take full
advantage of such a global approach, it is essential to focus
research programs on a limited number of well-validated basic con-
cepts common to autoimmunity, allergy and organ transplantation.
Thus, how to best enforce or end immune responses for the bene-
fit of the patients is probably the most exciting attainable goal for
today’s therapeutics [1].
Starting with this issue, we are pleased to launch a new review
series in the Journal of Cellular and Molecular Medicine, devoted
to present and discuss new approaches of potential relevance for
the development of translational immunology. Better treatments,
prevention and a cure, are the ultimate goals of multiple sclerosis
(MS) research, and perhaps no branch of investigation has proven
more fruitful towards these goals than the study of the immune
system. In the first review article appearing in this issue, Quintana,
Farez and Weiner at the Harvard University Center for Neurologic
Diseases, explore MS when complex data from multiple experi-
mental sources using interdisciplinary tools are integrated and
analyzed [2–4]. Current therapies for MS have emerged from our
growing understanding of how the immune system works and
how it can be manipulated to suppress or regulate immune
attacks. Here, they discuss how the development of computational
tools for the integration of multiple data into quantitative models
[5, 6], represents one of the last frontiers in drug discovery pro-
grams and the early detection of individuals at risk of suffering
MS. The series will go on with key questions with a clear empha-
sis on translational issues. Some of them are as follows: What is
the future of novel biochemical pathways and lipid-derived 
mediators as anti-inflammatory modulatory agents? Which are the
limits posed by the immune system to different gene therapy
strategies? What are the immune aspects of amyloidosis-based
diseases? What are the immunological problems and the prospec-
tive solutions for stem cell-based therapies? What can be learned
about the immune regulation of human haematopoietic stem
cells? What are the translational values of the immunomodulatory
capacities of mesenchymal stem cells? These, among other
issues, will highlight ongoing research to bring forth valuable
points and new ideas for discussion. Your comments, suggestions
and contributions aimed to integrate basic and clinical immunology,
will be warmly welcomed.
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